- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Opportunities for Easing BTK Inhibitor Switches
Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.
EP: 1.Fixed-Duration Options for CLL
EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study
EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
EP: 4.Sequencing Considerations in Relapsed/Refractory CLL
EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
EP: 8.Switching Between BTK Inhibitors in CLL
EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity
EP: 10.Opportunities for Easing BTK Inhibitor Switches
EP: 11.Reflections on 2024’s Progress in R/R CLL
Video content above is prompted by the following:
- What challenges do you face when switching between BTK inhibitors, and what strategies can help mitigate these challenges?
- How can oncologists better educate patients about the potential for switching BTK inhibitors to manage toxicities without compromising treatment outcomes?
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
